NASDAQ : DCOY
Decoy Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 805.88K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Decoy Therapeutics Inc. (DCOY) reported revenue of 227.63K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 227.63K | 1.84M | ||||
| Cost of Revenue | 1.86M | 8.55M | ||||
| Gross Profit | -1.63M | -6.71M | ||||
| Selling, General & Admin | 4.10M | 3.73M | 4.96M | 5.72M | 7.14M | 6.10M |
| Research & Development | 368.17K | 368.17K | 770.03K | 7.17M | 15.84M | |
| Operating Expenses | 4.46M | 4.10M | 5.73M | 12.89M | 22.98M | 6.10M |
| Operating Income | -6.10M | -4.10M | -5.73M | -12.89M | -22.98M | -12.81M |
| Interest & Investment Income | 167.27K | 95.47K | 158.54K | 352.25K | 218.73K | |
| Other Non Operating Income (Expenses) | 14.45K | 44.69K | ||||
| EBT Excluding Unusual Items | -5.93M | -4.00M | -5.58M | -12.54M | -22.74M | -12.77M |
| Impairment of Goodwill | -8.87M | |||||
| Pretax Income | -14.45M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Net Income | -14.45M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Net Income to Common | -14.45M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Shares Outstanding (Basic) | 357.69K | 96.97K | 80.18K | |||
| Shares Outstanding (Diluted) | 357.69K | 96.97K | 80.18K | |||
| EPS (Basic) | -40.40 | -129.10 | -69.54 | |||
| EPS (Diluted) | -40.40 | -129.10 | -69.54 | |||
| Free Cash Flow | -8.37M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Free Cash Flow Per Share | -23.39 | -49.78 | -56.44 | |||
| Operating Margin | -2,679.30% | -696.27% | ||||
| Profit Margin | -6,347.85% | -693.84% | ||||
| Free Cash Flow Margin | -3,675.70% | -554.29% | ||||
| EBITDA | -6.07M | -4.09M | -5.73M | -12.88M | -22.97M | -12.79M |
| D&A For EBITDA | 24.50K | 7.15K | 4.42K | 10.05K | 6.68K | 19.18K |
| EBIT | -6.10M | -4.10M | -5.73M | -12.89M | -22.98M | -12.81M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.29M | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Cash & Short-Term Investments | 8.29M | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Receivables | 1.61M | |||||
| Prepaid Expenses | 284.20K | 275.22K | 331.45K | 619.76K | 803.37K | 949.22K |
| Other Current Assets | 221.58K | |||||
| Total Current Assets | 8.57M | 10.99M | 2.99M | 6.52M | 14.52M | 30.16M |
| Property, Plant & Equipment | 399.08K | 40.56K | ||||
| Goodwill | 8.87M | |||||
| Long-Term Accounts Receivable | 1.61M | |||||
| Other Long-Term Assets | 28.77K | 30.99K | 35.41K | 66.85K | 130.50K | 193.87K |
| Total Assets | 9.00M | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Accounts Payable | 1.33M | 940.59K | 936.99K | 602.85K | 2.86M | 1.54M |
| Accrued Expenses | 215.70K | 859.44K | 352.42K | 406.75K | 1.41M | 567.79K |
| Short-Term Debt | 221.87K | 289.64K | ||||
| Current Unearned Revenue | 3.00M | 3.23M | ||||
| Other Current Liabilities | 139.82K | 142.13K | ||||
| Total Current Liabilities | 4.68M | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Total Liabilities | 4.68M | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Common Stock | 53.00 | 53.00 | 1.00 | 49.00 | 225.00 | 181.00 |
| Additional Paid-In Capital | 103.36M | 100.33M | 83.44M | 81.64M | 74.19M | 70.92M |
| Retained Earnings | -99.04M | -94.44M | -81.92M | -76.35M | -63.81M | -32.20M |
| Total Common Equity | 4.32M | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
| Shareholders' Equity | 4.32M | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
| Total Liabilities & Equity | 9.00M | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Total Debt | 221.87K | 289.64K | ||||
| Net Cash (Debt) | 8.29M | 10.71M | 2.21M | 5.61M | 12.11M | 29.21M |
| Net Cash Per Share | 23.17 | 110.45 | 27.59 | |||
| Filing Date Shares Outstanding | 655.18K | 531.97K | 1.30K | |||
| Total Common Shares Outstanding | 531.97K | 531.97K | 1.26K | |||
| Working Capital | 3.89M | 5.82M | 1.48M | 5.22M | 10.25M | 28.05M |
| Book Value Per Share | 8.12 | 11.07 | 30,805.88 | |||
| Tangible Book Value | 4.32M | 5.89M | 1.51M | 5.29M | 10.38M | 29.86M |
| Tangible Book Value Per Share | 8.12 | 11.07 | 23,752.65 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -14.45M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Depreciation & Amortization | 24.50K | 7.15K | 4.42K | 10.05K | 6.68K | 19.18K |
| Asset Writedown & Restructuring Costs | 8.52M | 8.52M | 10.85M | |||
| Stock-Based Compensation | 581.59K | 219.06K | 273.73K | 524.84K | 796.80K | 559.04K |
| Other Operating Activities | -6.54K | -6.54K | 130.00K | -14.45K | -44.69K | |
| Change in Accounts Receivable | 1.48M | 2.25M | ||||
| Change in Accounts Payable | -1.74M | -1.17M | 334.14K | -2.26M | 1.31M | -310.66K |
| Change in Unearned Revenue | -227.63K | |||||
| Change in Other Net Operating Assets | -1.02M | 120.72K | 438.14K | -193.35K | 1.06M | 99.66K |
| Operating Cash Flow | -8.32M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Capital Expenditures | -42.42K | |||||
| Sale (Purchase) of Intangibles | -1.50M | |||||
| Other Investing Activities | 1.34M | 1.34M | ||||
| Investing Cash Flow | 722.31K | 764.74K | -1.50M | |||
| Short-Term Debt Repaid | -221.87K | -466.50K | -280.92K | -477.03K | ||
| Total Debt Repaid | -221.87K | -466.50K | -280.92K | -477.03K | ||
| Net Debt Issued (Repaid) | -221.87K | -466.50K | -280.92K | -477.03K | ||
| Issuance of Common Stock | 15.10M | 12.56M | 1.53M | 6.92M | 1.99M | 28.77M |
| Financing Cash Flow | 15.10M | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
| Net Cash Flow | 7.49M | 8.28M | -3.47M | -6.21M | -17.11M | 18.10M |
| Free Cash Flow | -8.37M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Free Cash Flow Margin | -3,675.70% | -554.29% | ||||
| Free Cash Flow Per Share | -23.39 | -49.78 | -56.44 | |||
| Levered Free Cash Flow | -509.88K | 1.82M | -2.96M | -8.99M | -14.37M | -3.89M |
| Unlevered Free Cash Flow | -509.88K | 1.82M | -2.96M | -8.99M | -14.37M | -3.89M |
| Cash Interest Paid | 5.80K | 10.64K | 14.75K | 1.47K | ||
| Change in Working Capital | -2.99M | -1.05M | 772.29K | -968.33K | 2.37M | 2.03M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 678.12K | 4.14M | 2.65M | 2.56M | 3.49M | 22.39M |
| Enterprise Value | -7.61M | -667.63K | -303.59K | -4.56M | -13.33M | -9.51M |
| Last Close Price | 1.03 | 7.79 | 331.20 | 936.00 | 2,203.20 | 17,841.59 |
| PS Ratio | 2.98 | 12.17 | ||||
| PB Ratio | 0.13 | 0.70 | 1.75 | 0.48 | 0.34 | 0.58 |
| P/TBV Ratio | 0.16 | 0.70 | 1.75 | 0.48 | 0.34 | 0.75 |
| Debt / Equity Ratio | 0.15 | 0.06 | ||||
| Net Debt / Equity Ratio | -1.92 | -1.82 | -1.46 | -1.06 | -1.17 | -0.75 |
| Net Debt / EBITDA Ratio | 1.36 | 2.62 | 0.39 | 0.43 | 0.53 | 2.28 |
| Net Debt / FCF Ratio | 0.99 | 2.22 | 0.49 | 0.44 | 0.69 | 2.86 |
| Asset Turnover | 0.04 | 0.06 | ||||
| Quick Ratio | 1.77 | 2.07 | 1.61 | 4.54 | 3.21 | 13.84 |
| Current Ratio | 1.83 | 2.13 | 1.98 | 5.02 | 3.40 | 14.29 |
| Return on Equity (ROE) | -827.77% | -338.31% | -164.02% | -160.07% | -128.73% | -41.94% |
| Return on Assets (ROA) | -73.35% | -36.36% | -74.59% | -75.90% | -51.76% | -24.35% |
| Return on Capital Employed (ROCE) | -141.10% | -69.60% | -379.30% | -243.90% | -221.20% | -33.10% |
| Earnings Yield | -3,903.02% | -302.23% | -210.28% | -489.96% | -906.85% | -57.02% |
| FCF Yield | -1,233.85% | -116.54% | -170.66% | -501.81% | -504.82% | -45.55% |
| Buyback Yield / Dilution | -319.16% | -20.93% |